Ketamine and Midazolam
ApprovedSmall molecule
Ketamine and Midazolam is one of 26 small molecule programs targeting Sedation. It is currently in Approved.
2
Indications
3
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
167 competitors in Delirium
#DrugCompanyPhaseTrials
1Luvox
SSolvay Pharmaceuticals
Phase 3
Ketamine and Midazolam
KKasr El Aini Hospital
Approved
Rozerem
TakedaPreclinical
Inapsine
Alnylam PharmaceuticalsPreclinical
Anerem
AAcacia Pharma Ltd
Preclinical
Spravato
WWim Janssens
Preclinical
Raldesy
PPragma
Preclinical
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sedation2 trials
Ketamine Versus Etomidate for Procedural Sedation for Pediatric Orthopedic Reductions
Completed·—·Phase 4·NCT00596050·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ketamine and Midazolam. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- KKasr El Aini Hospital